Drug glossary Targeted therapy

Cediranib RECENTIN

A drug being studied in colorectal cancer trials. It appears in 7 clinical trials.

Oral VEGFR-1 VEGFR-2 VEGFR-3

United States Investigational

European Union Investigational

Spain Not available

What it is

Cediranib (AZD2171) is an oral small molecule tyrosine kinase inhibitor that targets multiple vascular endothelial growth factor receptors (VEGFRs). In colorectal cancer treatment, cediranib has been evaluated as an anti-angiogenic agent in combination with standard chemotherapy regimens including FOLFOX for both first-line and second-line treatment of metastatic disease. The drug works by blocking tumor blood vessel formation and growth, potentially enhancing the effectiveness of cytotoxic chemotherapy.

How it works

Cediranib selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinases, which are critical signaling pathways for angiogenesis and lymphangiogenesis. By blocking these receptors, the drug prevents the formation of new blood vessels that tumors require for growth and metastasis, effectively starving the tumor of nutrients and oxygen while also normalizing existing tumor vasculature.

Molecular targets

Common side effects

DiarrheaHypertensionFatigueDecreased appetiteNauseaHand-foot syndromeProteinuriaHypothyroidism

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.

Trials with this drug

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors NCT03851614 Active, not recruiting Phase 2 Canada Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advance… NCT02484404 Active, not recruiting Phase 1 United States Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial NCT01160926 Archived Phase 1 United Kingdom A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX NCT00494221 Archived Phase 1 Japan Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer NCT00399035 Archived Phase 3 Argentina, Australia, Brazil and 8 more First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX NCT00384176 Archived Phase 2 United States, Australia, Austria and 8 more

See all 7 trials

Guides that may help

Written for patients and families, in plain language.

RAS wild-type and left-sided colon cancer: cetuximab and panitumumab explained"RAS wild-type" means your tumour has no mutations in KRAS or NRAS. In that case anti-EGFR antibodies (cetuximab, panitumumab)…Eating during chemotherapy: what the evidence supports and what it does notThere is no "anti-cancer diet" that improves the outcome of chemotherapy. What is proven is that losing weight and muscle during…Cancer-related fatigue: what actually helpsCancer-related fatigue is the most common symptom during and after treatment, and it is not fixed by sleeping more. Before…

See all guides →